Efficacy of Thoracic Paravertebral Block in the Reduction of Acute Post-surgical Pain in Patients With Breast Cancer
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT02609321|
Recruitment Status : Completed
First Posted : November 20, 2015
Last Update Posted : December 26, 2016
|Condition or disease||Intervention/treatment||Phase|
|Breast Cancer||Procedure: Thoracic Paravertebral Block Procedure: Surgical Wound Infiltration||Phase 3|
Surgical treatment of breast cancer is frequently associated with postoperative pain in the surgical area, restricted movement of the ipsilateral upper limb and increased risk of chronic pain. This usually occurs even though management with analgesics commonly used in the postoperative period. Properly treatment of acute postoperative pain have essential implications: improving the general welfare of patients, can better withstand future medical interventions, facilitating recovery in the short and long term and is believed to have positive impact on survival from cancer.
Persistent pain after breast cancer management has considerable negative effects on the quality of life of survivors. Several risks factors have been described in preoperative, intra-operative and postoperative periods of persistent or chronic pain. In the postoperative period the most important risk factor is the severity of acute pain. For this, pain relief is an essential component of care of patients undergoing breast cancer surgery. Current evidence suggests that treatment of acute postoperative pain reduces the risk of persistent or chronic pain syndrome. The surgical wound infiltration with local anesthesia has been used routinely in patients managed at the Cancer Institute and Clinica Las Americas and is described as a safe and accessible procedure for the management of acute postoperative pain. Paravertebral block represents an interesting alternative in the management of perioperative pain, often used for breast surgery, hernia repair and thoracotomy in children and adults. Although complications associated with blocking are uncommon, the implementation of Ultrasound-guided approach has become the standard for performing said method.
Such considerations have led us to evaluate whether patients with breast cancer who are undergoing mastectomy, thoracic paravertebral block could be better in relief acute pain in comparison with surgical wound infiltration with local anesthesia. This will be studied by controlled randomized to one of two intervention groups (paravertebral block or local anesthesia with infiltration of the surgical wound) allocation trial. In all patients, general anesthesia and routine postoperative analgesic is used.
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||60 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||Single (Outcomes Assessor)|
|Official Title:||Efficacy of Thoracic Paravertebral Block vs Local Anesthesia of the Surgical Wound in Reduction of Acute Post-surgical Pain in Patients With Breast Cancer. Controlled Phase III, Randomized, Single-blind, Superiority Clinical Trial.|
|Study Start Date :||November 2015|
|Actual Primary Completion Date :||August 2016|
|Actual Study Completion Date :||December 2016|
Experimental: Thoracic Paravertebral Block
to identify the thoracic T3, a parallel line 2.5 cm from the spinous process is drawn and in this place the ultrasound sensor is placed. Ultrasonograph image identifies the transverse process, the intercostal cost-transverse ligament, the pleura and lung. We proceed to insert a needle between the two corresponding transverse processes and positions after passing the cost-ligament posterior intercostal and transverse to the parietal pleura. After negative aspiration for blood, 0.5% bupivacaine anesthetic is administered at doses of 1.5 mg/kg slowly. The volume is defined by the anesthesiologist. The injection of anesthetic is displayed, as well as confirmation of the correct location of the needle because the volume injected above pushes the pleura.
Procedure: Thoracic Paravertebral Block
Thoracic paravertebral block at T3 level with bupivacaine 0.5%, dosis 1.5mg/Kg
Active Comparator: Surgical Wound Infiltration
before the close of the skin, it proceeds to infiltrate the subcutaneous tissue and skin with 0.5% bupivacaine at doses of 1.5 mg/kg, generating the widest possible dissemination of the bupivacaine in the surgical area.
Procedure: Surgical Wound Infiltration
Surgical wound infiltration on the skin and subcutaneous tissue in surgical area with bipivacaine 0.5%, dosis 1.5mg/kg
- Acute post-surgical pain at rest and motion [ Time Frame: 24 hours ]Acute pain at rest and in motion at 2, 4, 6, 12 and 24 hours post operative, measured by a visual analog scale (0-100 mm) for the paravertebral block group compared with the surgical wound infiltration group.
- Adverse Events [ Time Frame: 2 months ]Compare the frequency and severity of adverse events in both groups
- Total doses of opioids [ Time Frame: 24 hours ]Compare the total dose of self-administered opioids analgesics for the first 24 hours
- Time to the first dose of opioids [ Time Frame: 24 hours ]Compare the time to first dose of opioids analgesics in both groups
- Post-mastectomy pain syndrome [ Time Frame: 2 months ]Compare the frequency of diagnosis of Post-mastectomy pain syndrome (SDP) two months after breast surgery in both groups
- Quality of life [ Time Frame: 2 months ]Estimate the changes in the quality of life of patients after two months after breast surgery in both groups
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02609321
|Instituto de Cancerología IDC Las Américas|
|Medellín, Antioquia, Colombia|
|Principal Investigator:||Fernando Herazo, MD, MSc||Instituto de Cancerología IDC Las Américas|
|Principal Investigator:||Hector I García, MD, MPH, MSc||Instituto de Cancerología IDC Las Américas|
|Principal Investigator:||Jorge A Egurrola, MD||Instituto de Cancerología IDC Las Américas|